Jose Espejo Valle-Inclan

Principal Investigator

Champalimaud Foundation
Country flagPortugal

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Accurate detection of somatic structural variants (SVs) and somatic copy number aberrations (SCNAs) is critical to study the mutational processes underpinning cancer evolution. Here we describe SAVANA, an algorithm designed to detect somatic SVs and SCNAs at single-haplotype resolution and estimate tumor purity and ploidy using long-read sequencing data with or without a germline control sample. We also establish best practices for benchmarking SV detection algorithms across the entire genome in a data-driven manner using replication and read-backed phasing analysis. Through the analysis of matched Illumina and nanopore whole-genome sequencing data for 99 human tumor-normal pairs, we show that SAVANA has significantly higher sensitivity and 13- and 82-times-higher specificity than the second and third-best performing algorithms. Moreover, SVs reported by SAVANA are highly consistent with those detected using short-read sequencing. In summary, SAVANA enables the application of long-read sequencing to detect SVs and SCNAs reliably.

Year:

2025

Year:

2025

Year:

2024

T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.

Year:

2024

Accurate detection of somatic structural variants (SVs) and copy number aberrations (SCNAs) is critical to inform the diagnosis and treatment of human cancers. Here, we describe SAVANA, a computationally efficient algorithm designed for the joint analysis of somatic SVs, SCNAs, tumour purity and ploidy using long-read sequencing data. SAVANA relies on machine learning to distinguish true somatic SVs from artefacts and provide prediction errors for individual SVs. Using high-depth Illumina and nanopore whole-genome sequencing data for 99 human tumours and matched normal samples, we establish best practices for benchmarking SV detection algorithms across the entire genome in an unbiased and data-driven manner using simulated and sequencing replicates of tumour and matched normal samples. SAVANA shows significantly higher sensitivity, and 9- and 59-times higher specificity than the second and third-best performing algorithms, yielding orders of magnitude fewer false positives in comparison to existing long-read sequencing tools across various clonality levels, genomic regions, SV types and SV sizes. In addition, SAVANA harnesses long-range phasing information to detect somatic SVs and SCNAs at single-haplotype resolution. SVs reported by SAVANA are highly consistent with those detected using short-read sequencing, including complex events causing oncogene amplification and tumour suppressor gene inactivation. In summary, SAVANA enables the application of long-read sequencing to detect SVs and SCNAs reliably in clinical samples.

Year:

2024

Accurate detection of somatic structural variants (SVs) and copy number aberrations (SCNAs) is critical to inform the diagnosis and treatment of human cancers. Here, we describe SAVANA, a computationally efficient algorithm designed for the joint analysis of somatic SVs, SCNAs, tumour purity and ploidy using long-read sequencing data. SAVANA relies on machine learning to distinguish true somatic SVs from artefacts and provide prediction errors for individual SVs. Using high-depth Illumina and nanopore whole-genome sequencing data for 99 human tumours and matched normal samples, we establish best practices for benchmarking SV detection algorithms across the entire genome in an unbiased and data-driven manner using simulated and sequencing replicates of tumour and matched normal samples. SAVANA shows significantly higher sensitivity, and 9- and 59-times higher specificity than the second and third-best performing algorithms, yielding orders of magnitude fewer false positives in comparison to existing long-read sequencing tools across various clonality levels, genomic regions, SV types and SV sizes. In addition, SAVANA harnesses long-range phasing information to detect somatic SVs and SCNAs at single-haplotype resolution. SVs reported by SAVANA are highly consistent with those detected using short-read sequencing, including complex events causing oncogene amplification and tumour suppressor gene inactivation. In summary, SAVANA enables the application of long-read sequencing to detect SVs and SCNAs reliably in clinical samples.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Ruoyan Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Peter Park

Harvard University

UNITED STATES
View details

Adrienne M Flanagan

Professor of Musculoskeletal Pathology

-

UNITED KINGDOM
View details

Anthony Moorman

Professor of Genetic Epidemiology

Newcastle University

UNITED KINGDOM
View details

Rita Cascão

Gulbenkian Institute for Molecular Medicine

PORTUGAL
View details

Chong Chu

Principal Investigator

The Wistar Institute

UNITED STATES
View details

Marc Mansour

Professor

University College London

UNITED KINGDOM
View details

Peter Ly

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Claudia Faria

Invited Assistant Professor

Universidade do Porto Faculdade de Medicina

PORTUGAL
View details

Isidro Cortes Ciriano

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Carolin Sauer

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details